|
rs12979860
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The <i>IL28B</i> rs12979860 CT/TT genotypes (OR = 3.44, 95% CI [2.12-5.58], <i>p</i> < 0.001), bAt haplotype (OR = 2.02, 95% CI [1.04-3.91], <i>p</i> = 0.03), pre-treatment serum HCV RNA (logIU/mL; OR = 1.73, 95% CI [1.31-2.28], <i>p</i> < 0.001), advanced liver fibrosis (OR = 1.68, 95% CI [1.10-2.58], <i>p</i> = 0.02), and HCV genotype 1 (OR = 1.59, 95% CI [1.07-2.37], <i>p</i> = 0.02) independently predicted poor response.
|
31565578 |
2019 |
|
rs12979860
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Multivariate analysis revealed IL28B rs12979860 CC genotype (OR = 3.12; 95% CI, 1.72-5.67; P < 0.001), hepatitis C virus RNA < 400,000 IU/ml (OR = 2.21; 95% CI, 1.22-3.99, P < 0.05), age < 45 years (OR = 2.03; 95% CI, 1.11-3.68; P < 0.05), and liver fibrosis stage 0-1 (OR = 1.64; 95% CI, 1.01-2.65, P < 0.05) were independent factors for SVR.
|
26339796 |
2015 |
|
rs12979860
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease.
|
25740255 |
2015 |
|
rs12979860
|
|
|
0.100 |
GeneticVariation |
BEFREE |
IL28B rs12979860 (IL28B) non-C/C, advanced liver fibrosis and high HCV RNA were considered as established risk factors for treatment failure.
|
24342953 |
2014 |
|
rs12979860
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Logistic regression analysis adjusting by [Age], [Sex], [HCV viral genotype], [HCV viral load], [HIV viral load], and [CD4 T cells levels] revealed the IL-28B rs12979860 (CT/TT) genotype as a protective factor against alanine aminotransferase (ALT) levels (>100 IU/L), aspartate aminotransferase (AST) levels (>75 IU/L), and AST-to-platelet ratio index (APRI) score for liver fibrosis (>1.5) [OR, (95% CI), p]: ALT [0.026 (0.001-0.576) 0.021]; AST [0.001 (0.000-0.297) 0.019]; APRI [0.031 (0.002-0.41) 0.008].
|
23030669 |
2013 |
|
rs12979860
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfected patients.
|
23835502 |
2013 |
|
rs12979860
|
|
|
0.100 |
GeneticVariation |
BEFREE |
During observation, 131 patients with chronic infection underwent a liver biopsy; age (OR 1.058; P = 0.01) G/T or G/G genotypes of rs8099917 polymorphism (OR 3.962; P = 0.001), and C/T or T/T genotypes of rs12979860 polymorphism (OR 3.494; P = 0.005) were associated with severe liver fibrosis, independent of liver iron concentration.
|
22180419 |
2012 |
|
rs12979860
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In a cross-sectional design, liver stiffness (transient elastography), surrogate markers of liver fibrosis (APRI and FIB-4 scores) and rs12979860 genotypes were analysed in 84 HCV/HIV co-infected patients.
|
21813376 |
2011 |
|
rs12979860
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The IL28B rs12979860 CC genotype is associated with a higher prevalence of cirrhosis in HIV-HCV-coinfected patients than CT/TT genotypes, suggesting that IL28B CC carriers may experience a more rapid progression of HCV-related liver fibrosis, perhaps as result of increased liver inflammation.
|
21592993 |
2011 |
|
rs12979860
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This translated into high rates of sustained viral response (SVR) among patients carrying CC(rs12979860) despite the presence of high viral load at baseline (SVR 74%), high age (SVR 79%) or severe liver fibrosis (SVR 83%).
|
21692944 |
2011 |
|
rs12979860
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In the multivariable analysis (odds ratio; 95% confidence interval; P value), the rs12979860 CC genotype was a strong predictor of SVR (3.7; 1.6-8.5; 0.002), independent of HCV genotype 3 (8.0; 3.1-21.0; <0.001), serum HCV-RNA less than 600,000 IU/ml (11.9; 3.8-37.4; <0.001) and lack of advanced liver fibrosis (3.5; 1.4-8.9; 0.009).
|
20389235 |
2010 |